抗体
选项
-
Rovelizumab (anti-CD11a&CD18)
- 简短描述: Purity≥95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG4
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 339086-79-2SMILES: [Rovelizumab] -
CD18 Mouse mAb关联靶标: ITGB2
- 简短描述: mAb (HI18a); Mouse anti Human CD18 Antibody; Flow; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Mouse IgG1
- 宿主种属: 小鼠(Mouse)
- 克隆号: HI18a
- 偶联: Unconjugated
-
Erlizumab (anti-CD18)关联靶标: ITGB2
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 211323-03-4 -
Ruplizumab (anti-CD40L)关联靶标: CD40LG
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 220651-94-5 -
Toralizumab (anti-CD40L)关联靶标: CD40LG
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 252662-47-8分子量: 148.43 (kD)SMILES: [Toralizumab] -
Frexalimab (anti-CD40L)关联靶标: CD40LG
- 简短描述: Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 2515463-86-0SMILES: [Frexalimab] -
Dapirolizumab (anti-CD40L)关联靶标: CD40LG
- 简短描述: Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
-
CD18 Rat mAb (Biotin)关联靶标: ITGB2
- 简短描述: mAb (M18/2); Rat anti Mouse CD18 Antibody (Biotin); Flow Cytometry
- 种属反应性: 小鼠(Mouse)
- 亚型: Rat IgG2a
- 宿主种属: 大鼠(Rat)
- 克隆号: M18/2
- 偶联: Biotin
首页
400-620-6333







